Currently Viewing:
Newsroom
Currently Reading
Ceritinib Approved as First Line for ALK-Positive Advanced NSCLC
May 30, 2017 – Surabhi Dangi-Garimella, PhD
What We're Reading: More Outcomes-Based Deals; Ebola Outbreak Small; Approving Expensive Drugs
May 29, 2017 – AJMC Staff
Overcoming Barriers to PCSK9 Prescriptions and Initial Denials
May 27, 2017 – Laura Joszt
This Week in Managed Care: May 26, 2017
May 26, 2017
Ahead of ASCO, Kite Pharma Announces Priority Review of Its CAR-T Treatment
May 26, 2017 – Surabhi Dangi-Garimella, PhD
Research Aims to Make Driving Safer for People With Diabetes
May 26, 2017 – Christina Mattina
5 Takeaways About Biosimilars at ISPOR
May 26, 2017 – Laura Joszt
Physician-Patient Responsible for Ban on Power Morcellators, Dies
May 25, 2017 – Surabhi Dangi-Garimella, PhD
What We're Reading: Renegotiating PDUFA; Americans Increase Exercise; Reducing Medical Waste
May 25, 2017 – AJMC Staff

Ceritinib Approved as First Line for ALK-Positive Advanced NSCLC

Surabhi Dangi-Garimella, PhD
Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.
Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene, as detected by an FDA-approved test, and who are treatment naïve can now be treated with the tyrosine kinase inhibitor ceritinib (Zykadia). The approval follows a priority review received in January 2017 for first-line in patients with ALK-positive metastatic NSCLC.

Results from the randomized, open-label, multicenter ASCEND-4 trial in patients newly diagnosed with ALK-positive NSCLC were the basis of the current approval. The rearrangement was detected using the VENTANA ALK (D5F3) test.

ASCEND-4 recruited 376 patients who were randomized 1:1 to receive once-daily ceritinib till disease progression or platinum-pemetrexed doublet chemotherapy (either cisplatin or carboplatin).

Patients were evaluated based on a blinded independent review committee assessment. Ceritinib treatment improved progression-free survival (PFS) by 8.5 months: median PFS was 16.6 months in the ceritinib arm (95% CI, 12.6 to 27.2) compared with 8.1 months in the chemotherapy arm (95% CI, 5.8 to 11.1). Patients treated with ceritinib had an objective response rate of 73% (95% CI, 66% to 79%) as opposed to 27% (95% CI, 21% to 34%) in the chemotherapy arm. The median duration of response was significantly greater among patients treated with ceritinib: 23.9 months (95% CI, 16.6 to not estimable), versus 11.1 months in those receiving chemotherapy.

Ceritinib also had an overall intracranial response rate of 57% in patients with brain metastases (95% CI, 37 to 76), versus 22% in those receiving chemotherapy (95% CI, 9 to 42).

It’s still too early to estimate overall survival in the enrolled population.

The most common adverse events (AEs) in patients receiving ceritinib were diarrhea, nausea, vomiting, fatigue, abdominal pain, decreased appetite, and cough. While serious AEs were noted in 38% of patients, a little over 10% of patients dropped out of the treatment arm because of AEs. Seventy-seven percent patients had a dose interruption while 66% required a dose reduction.

“Today's approval represents the next step in the development of Zykadia as a treatment option for ALK-positive metastatic NSCLC, bringing this important medication to a patient population where a need still exists,” said Bruno Strigini, CEO, Novartis Oncology, which has developed the drug.

Ceritinib was first approved in 2014 for late-stage NSCLC whose disease advanced on crizotinib or who were intolerant to crizotinib.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up